First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Encouraging early detection and breaking the silence around men’s health
The company is bringing precision therapies for gynaecological cancers
AINU is set to accelerate its expansion footprint, enhance operational capabilities
cSCC is one of the most common cancers in the U.S. and globally
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
